Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Genome Biology|November 19, 2016
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Genome Biology|March 3, 2017
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Cancer Cell|April 16, 2021
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacyChirag Krishna, Renzo G DiNatale, Fengshen Kuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Cancer Cell|April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Urologic Oncology|August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think TankDaniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
Cancer Cell|June 4, 2026
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinomaLynda Vuong, Andrew E Cornish, Jennifer Pfeil, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Genome Biology|November 19, 2016
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Genome Biology|March 3, 2017
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesYasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, et al.
Cancer Cell|April 16, 2021
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacyChirag Krishna, Renzo G DiNatale, Fengshen Kuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Cancer Cell|April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
Cancer Discovery|June 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell CarcinomaPhillip M Rappold, Lynda Vuong, Josef Leibold, et al.
Urologic Oncology|August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think TankDaniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
Cancer Cell|June 4, 2026
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinomaLynda Vuong, Andrew E Cornish, Jennifer Pfeil, et al.
Pageof 15